Rennova Health, Inc. · OTC:RNVA
Rennova Health — IPO Roadshow (December 2015)
17 slides from Rennova Health's IPO roadshow presentation, Dec 7, 2015
Slide 1: Diagnostics and supportive software solutions to healthcare providers
Filed Pursuant to Rule 433 Registration No. 333-208157 December 7, 2015 Nasdaq: RNVA Diagnostics and supportive software solutions to healthcare providers.
Slide 2: Free Writing Prospectus Statement
Free Writing Prospectus Statement This presentation highlights basic information about us and the proposed public offering. Because this presentation is a summary, it does not contain all of the information you should consider before investing in our common stock. We have filed a registration statem
Slide 3: Forward looking Statements and Non-GAAP Information
Forward looking Statements and Non-GAAP Information This presentation includes forward-looking statements about Rennova Health’s anticipated results that involve risks and uncertainties. Some of the information contained in this presentation, including statements as to industry trends and plans, obj
Slide 4: Offering Summary
Offering Summary Issuer: Rennova Health, Inc. Exchange & Ticker: NASDAQ: RNVA Expected Offering Approx. $15,000,000 (Common Stock and Warrants) Size Over-Allotment 15% (100% Primary) Use of Proceeds Working Capital; General Corporate Purposes; Continued development of new diagnostics processes and m
Slide 5: We are four years into our business plan with a number of significant milestones
NASDAQ: RNVA Listed on Nasdaq on November 3rd 2015 after completion of a merger between Medytox Solutions, Inc. and CollabRx, Inc. Expert Systems for Precision Medicine OTCBB since 2011 (MMMS) Nasdaq listed since 1995 CollabRx since 2012 (CLRX) • We are four years into our business plan with a numbe
Slide 6: Rennova Health is a vertically integrated diagnostics and software company
Rennova Health, Inc. is a vertically integrated company that provides industry leading Diagnostics and supportive software solutions to healthcare providers. Rennova Health owns and operates five high-complexity CLIA and CAP certified laboratories strategically located across the U.S International T
Slide 7: History
History Revenue of $57.9M Pre-merger numbers ADJUSTED from Medytox Revenue of EBITDA $41.89M $18.1M 2015 AJUSTED EBITDA 2014 Revenue of $14.33M $21.08M 2013 ADJUSTED EBITDA $4.18M Revenue of $3.99M 2012 Grew lab services ADJUSTED organically EBITDA Expanded lab Focused on Merger and Nasdaq $621K ser
Slide 8: Rennova Health offers a single source solution for Medical Providers
Rennova Health, Inc. offers a single source solution for Medical Providers Our core business is diagnostics: >95% of our revenue currently comes from diagnostics The diagnostics sector has changed dramatically in the last few years Medical providers need more than just diagnostics They need: Rennova
Slide 9: Our Brands
Our Brands Our solutions can be stand alone or integrated PFS offers medical receivables financing to medical providers. CollabRx enables efficient interpretation of diagnostics results into meaningful and useful information. MBC provides billing services for Rennova Health owned laboratories, Renno
Slide 10: Drug and Alcohol Rehabilitation and Pain Management markets
Drug and Alcohol Rehabilitation • Total Market Size – estimated at $35 Billion* • Large and growing number of facilities in a fragmented market • Between 14,500 to 16,700 outpatient clinics* • Market growth from high demand: • Over 23 million Americans are addicted to alcohol and other drugs** • The
Slide 11: 2015 Revenue 9 months: $42.2M
2015 Revenue 9 months: $42.2M (Pre-Merger numbers from Medytox) Diagnostics represents >95% of our revenue Jan-Sept 2015 $45,000,000 Transition year $42,220,000 $40,000,000 • Investment in Labs $35,000,000 • Investment in software $30,000,000 • Merger costs $25,000,000 • Billing Company restructure
Slide 12: Reconciliation of GAAP to Adjusted Measures - Medytox Solutions Pre Merger
Reconcilia3on of GAAP to Adjusted Measures - Medytox Solu3ons, Inc. Pre Merger (in thousands) 2011 2012 2013 2014 Jan-Sep 2015 $ $ Net Revenue 3,993 21,076 $ 41,889 $ 57,928 $ 28,921 Write-off of receivables aged greater than one year - - - - 13,298 $ $ Adjusted Revenue 3,993 21,076 $ 41,889 $ 57,928
Slide 13: Balance Sheet Highlights and Capitalization Table
Balance Sheet Highlights – September 30, 2015 (pro forma) Cash $ 6.7 Accounts Receivable, Net $ 22.7 Fixed Assets $ 7.8 Total Assets $ 48.0 Accounts Payable and Accrued Expenses $ 7.9 Debt $ 8.1 Capital Leases $ 4.0 Total Liabilities $ 24.6 Working Capital $ 11.6 Capitalization Table – November 30,
Slide 14: Management
Management: • Seamus Lagan CEO 20 years experience in the restructuring, development and management of startup and small companies • Jason Adams CFO CFO in behavorial health sector and Senior Financial Management of public companies • Sebastien Sainsbury Investor Relations Banking and wealth managem
Slide 15: Board
Board: • Thomas Mika Chairman of Rennova, CEO of CollabRx (subsidiary) 10 years as Chairman and CEO of a Nasdaq listed Company. Oversaw a number of public offerings. Holds a Bachelor of Science degree in Microbiology, MBA Harvard • Seamus Lagan CEO 20 years experience in the restructureing, developm
Slide 16: Product and solution rollout timeline
Existing 2015 2016 2017 Future Point of care test for Diabetes Test that will move from Lab to Doctors office @ @ (®) e@ Launch ) (Epinex) Cancer diagnostics (DNA Sequencing) | In planning @ @ lens? @ Two hurdles Callection and Iterpettion @ Oo ©@ @ Roll out Financial Solution i In planning e@ Launc
Slide 17: Key Highlights
Key Highlights • We are four years into our business plan with a number of significant milestones already achieved • We have revenue – Medytox had $57.9 million of sales in 2014 • Our operations are profitable, with Medytox having positive adjusted EBITDA of $18.1 million in 2014 • We operate in a s